Public Policy Resources

ACS CAN submitted comments on draft U.S. Food and Drug Administration (FDA) guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.

The House Energy and Commerce Committee sought community feedback on potential structural and policy changes at the National Institutes of Health.  ACS CAN offered suggestions related to NCI and the proposal's impacts on cancer research. 

Multi-Cancer Screening Tests Can Catch Cancer Early

Drug shortages have been a chronic issue for cancer patients, and ACS CAN has offered feedback to the Senate Finance Committee on their draft proposal to address root causes of the shortage.

The Clinical Trial Modernization Act (H.R. 8412) would increase access to clinical trials by allowing clinical trial sponsors to provide financial support to patients for costs associated with their trial participation, including medical cost-sharing like copays, and non-medical expenses such as travel, parking, food and lodging.

ACS CAN submitted comments on draft U.S. Food and Drug Administration (FDA) guidance on Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for Food and Drug Administration-Regulated Medical Products.

Drug shortages have had a significant impact on cancer patients, causing difficult decisions that have included rationed drugs, reduced or skipped doses, and altered treatment regimens which can lead to less effective treatments.

In response to a request from the National Institute of Starndards and Technology (NIST), ACS CAN has offered comments on the use of march-in rights to address drug costs.